Article
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Cancer discovery - 1 Jul 2018
Skoulidis Ferdinandos, Goldberg Michael E, Greenawalt Danielle M, Hellmann Matthew D, Awad Mark M, Gainor Justin F, Schrock Alexa B, Hartmaier Ryan J, Trabucco Sally E, Gay Laurie, Ali Siraj M, Elvin Julia A, Singal Gaurav, Ross Jeffrey S, Fabrizio David, Szabo Peter M, Chang Han, Sasson Ariella, Srinivasan Sujaya, Kirov Stefan, Szustakowski Joseph, Vitazka Patrik, Edwards Robin, Bufill Jose A, Sharma Neelesh, Ou Sai-Hong I, Peled Nir, Spigel David R, Rizvi Hira, Aguilar Elizabeth Jimenez, Carter Brett W, Erasmus Jeremy, Halpenny Darragh F, Plodkowski Andrew J, Long Niamh M, Nishino Mizuki, Denning Warren L, Galan-Cobo Ana, Hamdi Haifa, Hirz Taghreed, Tong Pan, Wang Jing, Rodriguez-Canales Jaime, Villalobos Pamela A, Parra Edwin R, Kalhor Neda, Sholl Lynette M, Sauter Jennifer L, Jungbluth Achim A, Mino-Kenudson Mari, Azimi Roxana, Elamin Yasir Y, Zhang Jianjun, Leonardi Giulia C, Jiang Fei, Wong Kwok-Kin, Lee J Jack, Papadimitrakopoulou Vassiliki A, Wistuba Ignacio I, Miller Vincent A, Frampton Garrett M, Wolchok Jedd D, Shaw Alice T, Jänne Pasi A, Stephens Philip J, Rudin Charles M, Geese William J, Albacker Lee A, Heymach John V
Abstract excerpt
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To...
Read the complete abstract on PubMed